The response rates (Table 2, Fig. 3b) were 2% for complete responses (CR: olaparib for BRCA2 mutation and high HRD score in prostate cancer, and capivasertib for PIK3CA mutation in breast cancer), 17% for partial responses (PR), 16% for stable disease (SD), and 65% for progressive disease (PD). Here, PIK3CA is linked to breast carcinoma.